FDA Clears Pathwork Diagnostics' Test for FFPE | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today said it has received clearance from the US Food and Drug Administration for its Tissue of Origin test for formalin-fixed paraffin embedded tissue.

The Pathwork Tissue of Origin test can now be broadly used on common clinical FFPE tumor specimens from both community and research hospitals, Pathwork Diagnostics said in a statement. The clearance also clears the way for additional FFPE-based cancer tests on its platform, the company added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.